CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Zura Bio's skin disease drug fails mid-stage trial

By Reuters News

Nov 9 (Reuters) - Zura Bio ZURA.O said on Monday its experimental drug failed the main goal of a mid-stage study in patients with hidradenitis suppurativa, a chronic skin disease that causes painful lumps under the skin.

Shares of the biotech firm fell more than 70% in premarket trading.


  • The company said tibulizumab failed the study's main goal of showing a benefit over placebo in reducing abscesses and inflammatory skin nodules after 16 weeks

  • Key secondary goals were also missed, including measures tracking the proportion of patients achieving at least 50% and 75% reductions in disease lesions

  • Zura said it will discontinue tibulizumab's development for hidradenitis suppurativa but continue studying it in systemic sclerosis, which can cause hardens the skin and organs, and polymyalgia rheumatica, an inflammatory condition causing muscle pain and stiffness

  • The trial enrolled 247 adults with moderate-to-severe hidradenitis suppurativa who were randomly assigned to receive one of two doses of tibulizumab or placebo

  • The two tibulizumab doses reduced lesion counts by 56% and 58.1%, respectively, versus a 52.5% reduction in the placebo group, the company said

  • It added the drug was well tolerated, while one death in the higher-dose group was considered unrelated to treatment by the study investigator

  • Zura said it had $187.7 million in cash and cash equivalents as of September 30, which it expects will support planned operations through at least the end of 2028

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.